BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 16760988)

  • 1. US court rules to allow experimental drugs for dying patients.
    Waltz E
    Nat Med; 2006 Jun; 12(6):596. PubMed ID: 16760988
    [No Abstract]   [Full Text] [Related]  

  • 2. Dying to live.
    Nat Med; 2006 Jun; 12(6):593. PubMed ID: 16760985
    [No Abstract]   [Full Text] [Related]  

  • 3. Access before approval--a right to take experimental drugs?
    Okie S
    N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
    [No Abstract]   [Full Text] [Related]  

  • 4. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
    Ochs A
    Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
    [No Abstract]   [Full Text] [Related]  

  • 5. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 6. The proper focus for FDA regulations: why the fundamental right to self-preservation should allow terminally ill patients with no treatment options to attempt to save their lives.
    Puckett A
    SMU Law Rev; 2007; 60(2):635-65. PubMed ID: 17849632
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulating the fate of pharmaceutical drugs: a new prescription for the environment.
    Nidel CT
    Food Drug Law J; 2003; 58(1):81-101. PubMed ID: 12739585
    [No Abstract]   [Full Text] [Related]  

  • 8. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move.
    Moss RW
    New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 10. To market, to market. The nuts and bolts of prescription drug approval.
    Peterson AM
    Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443
    [No Abstract]   [Full Text] [Related]  

  • 11. Safe drugs and the cost of good intentions.
    Eichler HG; Abadie E; Raine JM; Salmonson T
    N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718
    [No Abstract]   [Full Text] [Related]  

  • 12. Drive for drugs leads to baby clinical trials.
    Nature; 2006 Mar; 440(7083):406-7. PubMed ID: 16554774
    [No Abstract]   [Full Text] [Related]  

  • 13. Individual patient treatment use of unapproved drugs: a new option for the seriously ill.
    Simon LS; Green A
    J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):19-22. PubMed ID: 20345195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric drug development in anesthesiology: an FDA perspective.
    Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
    Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
    [No Abstract]   [Full Text] [Related]  

  • 15. Mandatory comparator trials for therapeutically similar drugs: an assessment of the facts.
    Milne CP; Kaitin KI; Dimasi JA
    Am J Ther; 2007; 14(3):231-4. PubMed ID: 17515695
    [No Abstract]   [Full Text] [Related]  

  • 16. Sources of variability in clinical trials of new drugs for epilepsy.
    Leppik IE
    Epilepsy Res Suppl; 1993; 10():157-66. PubMed ID: 8251091
    [No Abstract]   [Full Text] [Related]  

  • 17. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
    Lovell MC
    Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202
    [No Abstract]   [Full Text] [Related]  

  • 18. The regulation of drugs and biologics: fifty years into the future.
    Kuhlik BN
    Food Drug Law J; 2000; 55(1):21-5. PubMed ID: 12269358
    [No Abstract]   [Full Text] [Related]  

  • 19. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
    Breslow LH
    Harvard J Legis; 2003; 40(1):133-93. PubMed ID: 16594116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.